Stabilis

Scopolamine N-butyl bromide



Noms commerciaux

Buscapina	Espagne
Buscolysin	Pologne
Buscopan	Allemagne, Australie, Autriche, Belgique, Brésil, Canada, Egypte, Emirats Arabes Unis , Finlande, Islande, Luxembourg, Norvège, Nouvelle Zélande, Pays bas, Portugal, Suède, Suisse, Tunisie, Turquie
Butilbromuro de hioscina	Argentine, Colombie
Cifespasmo	Argentine
Colobolina	Argentine
Dolopina	Equateur
Escopolamina N butyl bromuro	Chili
Hiocin	Vénézuela
Hioscina	Argentine, Colombie, Pérou
Hioscina butil bromuro	Colombie, Pérou
Hyocidic	Iran
Hyoscine	Australie
Hyoscine hydrobromide	Canada
Hyotex	Iran
Pasmodina Drawer	Argentine
Rupe N	Argentine
Scoburen	France
Selpirans	Vénézuela
Spasmopan	Tunisie
Xemol	Turquie

Stabilité en mélange

PP	▲	5 & 6,67 mg/ml	25°C		Haloperidol lactate : 0,42 & 0,62 mg/ml Morphine hydrochloride : 1,67>> 10 mg/ml	15		2055
PP	▲	3,33>>6,67 mg/ml	25°C		Tramadol hydrochloride : 8,33>>33,3 mg/ml	15		2176
PP	▲	3,33>>6,67 mg/ml	25°C		Morphine hydrochloride : 1,67>> 10 mg/ml	15		1966

PP	2,5 & 5 & 10 mg/ml	4°C		Haloperidol lactate : 0,312 mg/ml	15		1970
PP	3,33>>6,67 mg/ml	4°C		Tramadol hydrochloride : 8,33>>33,3 mg/ml	15		2176
PP	3,33>>6,67 mg/ml	4°C		Morphine hydrochloride : 1,67>> 10 mg/ml	15		1966
PP	0,85 mg/ml	32°C		Fentanyl citrate : 40 µg/ml Midazolam hydrochloride : 0,6 mg/ml	10		1405
?	3,33 >> 6,67 mg/ml	25°C		Tramadol hydrochloride : 8,8 >> 33,3 mg/ml Haloperidol lactate : 0,208 >> 0,624 mg/ml	15		3132

Compatibilités

	✓	Scopolamine N-butyl bromide : 1.68 & 5 mg/ml Dexamethasone sodium phosphate : 0.44 & 1.33 mg/ml		1971
	✓	Scopolamine N-butyl bromide : 3-7 mg/ml Dexamethasone sodium phosphate : 0.2 >> 0.4 mg/ml		4404
	✓	Scopolamine N-butyl bromide : 2.35 >> 8 mg/ml Diamorphine hydrochloride : 41.67 >> 132.35 mg/ml	∅	1230
	✓	Scopolamine N-butyl bromide Furosemide : 1 mg/ml		1232
	✓	Scopolamine N-butyl bromide : 1.68 & 5 mg/ml Haloperidol lactate : 0.21 & 0.62 mg/ml		1971
	✓	Scopolamine N-butyl bromide : 2,5 >> 10 mg/ml Haloperidol lactate : 0,3125 >> 1,25 mg/ml		1970
	✓	Scopolamine N-butyl bromide : 3-7 mg/ml Haloperidol lactate : 0.25 >> 0.5 mg/ml		4404
	✓	Scopolamine N-butyl bromide : 0.4 mg/ml Ketoprofene : 3.2 mg/ml		1847
	✓	Scopolamine N-butyl bromide : 3-7 mg/ml Levomepromazine : 0.625 >> 2.5 mg/ml		4404
	✓	Scopolamine N-butyl bromide : 3-7 mg/ml Metoclopramide hydrochloride : 3 mg/ml		4404
	✓	Scopolamine N-butyl bromide : 1.68 & 5 mg/ml Metoclopramide hydrochloride : 1.11 & 3.33 mg/ml		1971
	✓	Scopolamine N-butyl bromide : 3-7 mg/ml Midazolam hydrochloride : 1.2 mg/ml		4404
	✓	Scopolamine N-butyl bromide : 1.68 & 5 mg/ml Midazolam hydrochloride : 0.5 & 1.5 mg/ml		1971
	✓	Scopolamine N-butyl bromide : 1.68 & 5 mg/ml Morphine hydrochloride : 1.68 & 5 mg/ml		1971
	✓	Scopolamine N-butyl bromide : 3-7 mg/ml Morphine hydrochloride : 2 >> 5 mg/ml		4404
	✓	Scopolamine N-butyl bromide : 3.33 >> 6.67 mg/ml Morphine hydrochloride : 1.67 >> 10 mg/ml		1966
	✓	Scopolamine N-butyl bromide : 10 mg/ml Morphine hydrochloride : 2.5 >> 15 mg/ml		1757
	✓	Scopolamine N-butyl bromide : 0.88 & 4.6 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml		2900

	✓	Scopolamine N-butyl bromide : 0.88 & 4.6 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml		2900
	✓	Scopolamine N-butyl bromide : 1 & 2.6 mg/ml Oxycodone hydrochloride : 1 & 8.7 mg/ml		2125
	✓	Scopolamine N-butyl bromide : 1 & 2.6 mg/ml Oxycodone hydrochloride : 1 & 8.7 mg/ml		2125
	✓	Scopolamine N-butyl bromide : 1.68 & 5 mg/ml Tramadol hydrochloride : 11.18 & 33.3 mg/ml		1971
	✓	Scopolamine N-butyl bromide : 3,33>>6,67 mg/ml Tramadol hydrochloride : 8,33>>33,3 mg/ml		2176

Voie d'administration

Bibliographie

	Type	Source
1230	Revue	Regnard C, Pashley S, Westrope F. Anti-emetic / diamorphine mixture compatibility in infusion pumps. Br J Pharm Pract 1986 ; 8: 218-220.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1405	Revue	Peterson GM, Miller KA, Galloway JG, Dunne PF. Compatibility and stability of fentanyl admixtures in polypropylene syringes. J Clin Pharm Ther 1998 ; 23: 67-72.
1757	Revue	Schrijvers D, Tai-Apin C, De Smet MC, Cornil P, Vermorken JB, Bruyneel P. Determination of compatibility and stability of drugs used in palliative care. J Clin Pharm Ther 1998 ; 23: 311-314.
1847	Revue	Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G. Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration. J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241.
1966	Revue	Barcia E, Reyes R, Azuara L, Sànchez Y, Negro S. Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide. Support Care Cancer 2005 ; 13, 4: 239-245.
1970	Revue	Barcia E, Reyes R, Azuara M.L, S?nchez Y, Negro S. Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2003 ; 11, 2: 107-113.
1971	Revue	Azuara ML, Sanchez Y, Reyes R, Barcia E. Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2001

2055	Revue	Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E. Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients. Int J Pharm 2006 ; 307: 278-284.
2125	Revue	Gardiner PR. Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. Hospital Pharmacist 2003 ; 10: 354-361.
2176	Revue	Barcia E, Martin A, Azuara ML, Sanchez Y, Negro S. Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability. Support Care Cancer 2007 ; 15: 57-62.
2900	Revue	Hines S, Pleasance S. Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration. EJHP 2009 ; 15, 5: 32-38.
3132	Revue	Negro S, Martin A, Azuara L, Sanchez Y, Barcia E. Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine. J Palliat Med 2010 ; 13, 3: 273-277.
4404	Poster	Müller U, Haller F, Wiedemeier P, Steuer C. Compatibility studies of seven commonly used drugs for parenteral administration in palliative care. JFSPH 2019 2019

Dictionnaire

Antimuscarinique	Injectable
Noms commerciaux	Stabilité en mélange
Contenant	Solvant
Concentration	Température
Conservation	Molécule
Durée de stabilité	Bibliographie
Polypropylène	Chlorure de sodium 0,9%
A l'abri de la lumière	Jour
Seringue polypropylène	Eau pour préparation injectable
Non précisé	Compatibilités
Compatible	NaCl 0,9% ou glucose 5%
Aucun	Voie d'administration
Intraveineuse	Perfusion intraveineuse
Intramusculaire	Sous cutanée
Perfusion SC continue	Bibliographie
Dictionnaire	